AusCann Group Holdings Ltd. announce that it has completed a 90-day Target Animal Safety study (TAS) for DermaCann®, confirming the product to be safe and well tolerated for use in dogs at up to 5 times the current planned dose. The TAS study is a requirement for the DermaCann® regulatory submissions in Australia and New Zealand. Subject to approval, DermaCann® would be the first and only registered, cannabinoid-based veterinary product to be legally supplied via prescription through Australian and New Zealand veterinarians. The safety study was completed at a veterinary research site in the United States and 15 healthy beagles were randomised into three groups for the trial (5 dogs per group). Dogs treated with DermaCann for 92 days at 3X and 5X the planned upper dose rate were clinically well tolerated with no clinically relevant nor statistical differences between treated and control dogs identified for all physical examinations, clinical observations, haematology and food/water consumption parameters. Haematological parameters for all dogs remained within normal ranges with no difference compared to untreated dogs. Serum chemistry was also largely unimpacted by treatment. A mild increase in alkaline phosphatase (ALP) was observed with the 3X and 5X DermaCann® treatments compared to placebo which is a well-documented response to CBD in humans and animals.